SCHEMBL2886844

SCHEMBL2886844

NCCCCC(N)(NC(N)=O)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ODC1 P11926 2/20 0.40
LMNA P02545 3/20 0.38
BLM P54132 3/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
PMP22 Q01453 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CYP2D6 P10635 1/20 0.35
NFKB1 P19838 1/20 0.35
NPSR1 Q6W5P4 2/20 0.34
THRB P10828 2/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
PLG P00747 1/20 0.34
ALOX15 P16050 1/20 0.34
SLC6A2 P23975 1/20 0.34
RECQL P46063 1/20 0.34
SLC6A3 Q01959 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4727982 0.79 ODC1 (0.43) ODC1LMNABLMKDM4EMAPT
SCHEMBL3818403 0.76 ALDH1A1 (0.35) LMNATHRBKMT2AMEN1ALDH1A1
SCHEMBL23217861 0.75 ODC1 (0.33) ODC1LMNABLMKDM4EMAPT
SCHEMBL997199 0.74 ODC1 (0.48) ODC1LMNABLMKDM4EMAPT
SCHEMBL997201 0.74 ODC1 (0.48) ODC1LMNABLMKDM4EMAPT
SCHEMBL997202 0.74 ODC1 (0.48) ODC1LMNABLMKDM4EMAPT
SCHEMBL30496170 0.73 ARG1 (0.31) ARG1ARG2
SCHEMBL9501854 0.71 ODC1 (0.61) ODC1LMNABLMKDM4EMAPT
SCHEMBL2115160 0.70 ODC1 (0.48) ODC1LMNABLMKDM4EMAPT
SCHEMBL2587404 0.70 ODC1 (0.48) ODC1LMNABLMKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7722858-B2 Prevention and treatment of atherosclerosis by reducing carbamylation of LDL or the effects of carbamylated LDL BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2010-05-25 US disclosed
US-7476551-B2 Diagnosing atherosclerosis risk by measuring carbamylated low density lipoprotein levels THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2009-01-13 US disclosed
WO-2007092625-A2 PREVENTION AND TREATMENT OF ATHEROSCLEROSIS BY REDUCING CARBAMYLATION OF LDL OR THE EFFECTS OF CLDL THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2007-08-16 WO disclosed
US-20060183245-A1 Prevention and treatment of atherosclerosis by reducing carbamylation of LDL or the effects of carbamylated LDL BIOVENTURES, LLC 2006-08-17 US disclosed
US-20030045004-A1 Prevention and treatment of atherosclerosis by reducing carbamylation of LDL or the effects of carbamylated LDL VETERANS AFFAIRS, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF 2003-03-06 US disclosed